Logo image
Back
Towards the Integration of an Anti-Contractile Compound Within Drug-Coated Balloon Therapy
Journal article   Open access   Peer reviewed

Towards the Integration of an Anti-Contractile Compound Within Drug-Coated Balloon Therapy

Dima BaniHani, John F Eberth, Francis G Spinale, Vipul C Chitalia, Jahid Ferdous, Vijaya B Kolachalama and Tarek Shazly
Cardiovascular engineering and technology
25 Jul 2025
DOI: https://doi.org/10.1007/s13239-025-00798-7
PMID: 40716000
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1007/s13239-025-00798-7View
Published, Version of Record (VoR) Open

Abstract

Drug-coated balloon Urea Anti-contractile Valsartan Paclitaxel
Drug-coated balloon (DCB) therapy is a promising approach to treat peripheral artery disease (PAD), wherein lesion site preparation, balloon inflation, and the local delivery of anti-proliferative drugs such as paclitaxel (PTX) restores and retains lumen patency. Although largely successful in PAD applications, broader clinical deployment is in part limited by the occurrence of late lumen loss due to inward vessel remodeling at the treatment site, a maladaptive chronic response that has been clinically-observed to coincide with elevations in resident vascular smooth muscle cell (vSMC) tone. This study aims to explore a novel strategy to improve DCB efficacy via drug-based attenuation of vSMC tone at the treatment site. As a strategy to mitigate this post-DCB failure mode, we consider the local co-delivery of PTX and an additional drug that induces relaxation of vSMCs, specifically the clinically-approved anti-hypertensive drug valsartan (VAL). The potential benefit of drug-based regulation of vSMC tone is supported by recent theoretical studies that predict inward remodeling in the presence of hypertension and endothelial cell dysfunction, both common co-morbidities in PAD patients and established causes of elevated vSMC contractility. The specific selection of VAL as the anti-contractile payload constituent is motivated by its well-known pharmacokinetic and safety profiles, and the notion that current clinical use and familiarity could promote rapid translation in the context of DCBs. Our obtained results quantify the potency of VAL to induce local vSMC relaxation in arterial tissue, demonstrate the feasibility of PTX and VAL co-delivery using the canonical excipient urea for balloon coating formation, and elucidate key structure-function relations to facilitate efficient drug delivery with these novel coatings. Our study supports the continued evaluation of VAL for inclusion in DCB formulations due to its potential to redirect post-treatment arterial remodeling. Future in-vivo studies which examine the co-delivery of PTX and VAL in the context of DCBs are needed to establish both the safety and efficacy of this novel approach.

Metrics

1 Record Views

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Cardiac & Cardiovascular Systems
Engineering, Biomedical
Logo image